The Paul G. Allen Frontiers Group, in partnership with the American Heart Association, has announced the launch of a $43 million program aimed at accelerating research in the areas of cerebrovascular and neurodegenerative diseases.
The initiative seeks to shed light on how to better detect, prevent, and treat age-related cognitive impairments, including Alzheimer's disease, one of the most common forms of dementia. With additional funding from other contributors, including the Oskar Fischer Project, the AHA/Allen initiative will work to identify and fund highly promising teams of bioscience investigators pursuing creative, transformative ideas that can advance the science of brain health and cognitive impairment.
"Alzheimer's, dementia, and other cognitive ailments have become an enormous emotional and economic burden for our society," said Frontiers Group executive director Tom Skalak. "This new American Heart Association-Allen initiative will create new bridges and collaborations between researchers and physicians, ultimately leading to better understanding and treatment of these cognitive disorders."
The initial deadline for proposals is July 6. For more details, see the AHA website.